ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRIS vs SCNI // EV/EBITDA & P/E VALUATION

Curis Inc. (NASDAQ) VS. Scinai Immunotherapeutics Ltd. (NASDAQ) • 15-METRIC TALLY: CRIS 2 — SCNI 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRIS VS. SCNI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRIS SCNI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — -30.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -13.40% 99.20% -112.60 SCNI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 SCNI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.2 22.7 +19.50 CRIS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.7M $1.4M $2.3M CRIS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRIS REV SCNI REV CRIS GROSS % SCNI GROSS % CRIS FCF SCNI FCF
FY 2025 $9.4M $1.3M — -50.0% -$27.2M -$6.1M
FY 2024 $10.9M $658.0K — -50.0% -$39.6M -$6.3M
FY 2023 $10.0M $0 — — -$38.4M -$9.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRIS // BETA —
SCNI // BETA —